Showing results (151-160 of 164) with videos related to
Sort By:
Pageof 17
Surgery|July 14, 2023
Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort studyJesse V Groen, Nynke Michiels, Marc G Besselink, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter StudyLeonard W F Seelen, Simone Augustinus, Thomas F Stoop, et al.The British Journal of Surgery|July 13, 2023
Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trialsDeesje Doppenberg, Jacob L van Dam, Youngmin Han, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 5, 2026
The density of tumour infiltrating lymphocytes in oesophago-gastric cancer varies with disease stage, geographical region and treatment: a post hoc analysis of nine phase III clinical trialsGeorgina A Keogh, Nina Šefčovičová, Tomio Arai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2020
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC TrialEva Versteijne, Mustafa Suker, Karin Groothuis, et al.BMJ Open|July 16, 2025
STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II studySuus Y van Loosbroek, Maaike T W Milder, Dirk de Ruysscher, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 24, 2019
The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysisTara M Mackay, F Jasmijn Smits, Daphne Roos, et al.European Journal of Cancer (Oxford, England : 1990)|July 14, 2026
Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancerNicole D Hildebrand, David P J van Dijk, Jisce R Puik, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2022
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC TrialEva Versteijne, Jacob L van Dam, Mustafa Suker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 TrialRuth A L Willems, Aniek E van Diepen, Esther N Dekker, et al.Pageof 17